Tissue plasminogen activator and chronic kidney disease: More than a simple protease

Plasminogen Activator: Genetic Factors, Functions and Clinical Applications

Volumn , Issue , 2014, Pages 53-68

  Lin, Ling ^a   Hu, Kebin ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84948970444     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (54)

1. Hu K, Mars WM, Liu Y. Novel actions of tissue-type plasminogen activator in chronic kidney disease. Front Biosci 2008; 13: 5174-5186.
2. Yang J, Shultz RW, Mars WM, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110: 1525-1538.
3. Hu K, Lin L, Tan X, et al. tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J Am Soc Nephrol 2008; 19: 503-514.
4. Hu K, Wu C, Mars WM, et al. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest 2007; 117: 3821- 3832.
5. Hu K, Yang J, Tanaka S, et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281: 2120-2127.
6. Lin L, Bu G, Mars WM, et al. tPA activates LDL receptor-related protein 1-mediated mitogenic signaling involving the p90RSK and GSK3beta pathway. Am J Pathol 2010; 177: 1687-1696.
7. Lin L, Wu C, Hu K. Tissue Plasminogen Activator Activates NFkappaB through a Pathway Involving Annexin A2/CD11b and Integrin- Linked Kinase. J Am Soc Nephrol 2012; 23: 1329-1338.
8. Vivien D, Gauberti M, Montagne A, et al. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab 2011; 31: 2119-2134.
9. Olson ST, Swanson R, Day D, et al. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin. Biochemistry 2001; 40: 11742-11756.
10. Roelofs JJ, Rouschop KM, Leemans JC, et al. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006; 17: 131-140.
11. Cao C, Lawrence DA, Li Y, et al. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. Embo J 2006; 25: 1860-1870.
12. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, et al. Is tissue-type plasminogen activator a neuromodulator? Mol Cell Neurosci 2004; 25: 594-601.
13. Benarroch EE. Tissue plasminogen activator: beyond thrombolysis. Neurol 2007; 69: 799-802.
14. Shi Y, Mantuano E, Inoue G, et al. Ligand binding to LRP1 transactivates Trk receptors by a Src family kinase-dependent pathway. Sci Signal 2009; 2: ra18.
15. Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-1540.
16. Nagai N, Yamamoto S, Tsuboi T, et al. Tissue-type plasminogen activator is involved in the process of neuronal death induced by oxygen-glucose deprivation in culture. J Cereb Blood Flow Metab 2001; 21: 631-634.
17. Welling TH, Huber TS, Messina LM, et al. Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasminindependent, receptor-mediated mechanism. J Surg Res 1996; 66: 36-42.
18. Ortiz-Zapater E, Peiro S, Roda O, et al. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol 2007; 170: 1573-1584.
19. Wang X, Asahi M, Lo EH. Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. Neurosci Lett 1999; 274: 79-82.
20. Armstead WM, Nassar T, Akkawi S, et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 2006; 9: 1150- 1155.
21. Bu G, Williams S, Strickland DK, et al. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1992; 89: 7427-7431.
22. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-3358.
23. Huang SS, Ling TY, Tseng WF, et al. Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1. Faseb J 2003; 17: 2068-2081.
24. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108: 779-784.
25. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, et al. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008; 88: 887-918.
26. Obermoeller-McCormick LM, Li Y, Osaka H, et al. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci 2001; 114: 899-908.
27. Hussain MM. Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family. Front Biosci 2001; 6: D417-428.
28. Strickland DK, Ranganathan S. Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J Thromb Haemost 2003; 1: 1663-1670.
29. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin IImediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203.
30. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-3358.
31. Kim J, Hajjar KA. Annexin II: a plasminogen-plasminogen activator coreceptor. Front Biosci 2002; 7: d341-348.
32. Babbin BA, Parkos CA, Mandell KJ, et al. Annexin 2 regulates intestinal epithelial cell spreading and wound closure through Rhorelated signaling. Am J Pathol 2007; 170: 951-966.
33. Rescher U, Gerke V. Annexins--unique membrane binding proteins with diverse functions. J Cell Sci 2004; 117: 2631-2639.
34. Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987-9993.
35. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23: 1917-1928.
36. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
37. Na SY, Sung JY, Chang JH, et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 2011; 33: 121-130.
38. Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010; 55: S1-420, A426-427.
39. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009; 5: 319- 328.
40. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2992-2998.
41. Kaissling B, Le Hir M. The renal cortical interstitium: morphological and functional aspects. Histochem Cell Biol 2008; 130: 247-262.
42. Bohle A, Strutz F, Muller GA. On the pathogenesis of chronic renal failure in primary glomerulopathies: a view from the interstitium. Exp Nephrol 1994; 2: 205-210.
43. Neilson EG. Mechanisms of disease: Fibroblasts--a new look at an old problem. Nat Clin Pract 2006; 2: 101-108.
44. Qi W, Chen X, Poronnik P, et al. The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int J Biochem Cell Biol 2006; 38: 1-5.
45. Muller GA, Zeisberg M, Strutz F. The importance of tubulointerstitial damage in progressive renal disease. Nephrol Dial Transplant 2000; 15 Suppl 6: 76-77.
46. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000; 13 Suppl 3: S111-120.
47. Muller GA, Rodemann HP. Characterization of human renal fibroblasts in health and disease: I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys with histologically proven interstitial fibrosis. Am J Kidney Dis 1991; 17: 680-683.
48. Rodemann HP, Muller GA, Knecht A, et al. Fibroblasts of rabbit kidney in culture. I. Characterization and identification of cell-specific markers. Am J Physiol 1991; 261: F283-291.
49. Harris RC, Neilson EG. Toward a unified theory of renal progression. Annu Rev Med 2006; 57: 365-380.
50. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
51. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
52. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280- 288.
53. Sanz AB, Sanchez-Nino MD, Ramos AM, et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262.
54. Zhang X, Polavarapu R, She H, et al. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-kappaB pathway activation. Am J Pathol 2007; 171: 1281-1290.